Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksABC.L Regulatory News (ABC)

  • There is currently no data for ABC

Director/PDMR Shareholding

4 Nov 2009 10:00

RNS Number : 9236B
ABCAM Plc
04 November 2009
 



For immediate release

4 November 2009

 ("Abcam" or "the Company")

Director and PDMR Dealings

Cambridge, UK: Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online catalogue, announces the following transactions undertaken bemployees of the Company:

On 3 November 2009, Jim Warwick, as Executive Director of the Company, exercised share options over 4,218 ordinary shares of 1 pence each in the Company at an exercise price of 224p per share. Following this transaction, Mr Warwick's total beneficial interest in the Company is 857,738 ordinary shares representing approximately 2.4 per cent. of the current issued share capital of the Company. 

Also on 3 November 2009, Jane Cookea PDMR of the Company, exercised share options over 3,375 ordinary shares of 1 pence each in the Company at an exercise price of 224p per share. Following this transaction, Mrs Cooke's total beneficial interest in the Company is 3,724 ordinary shares representing approximately 0.01 per cent. of the current issued share capital of the Company. 

For further information please contact:

Abcam

+ 44 (0) 1223 696000

Jonathan Milner, Chief Executive Officer

 

Jeffrey Iliffe, Chief Financial Officer

 

Numis Securities

+ 44 (0) 20 7260 1000

Michael Meade / Nick Westlake - Nominated Adviser

 

James Black - Corporate Broking

 

Buchanan Communications

+ 44 (0) 20 7466 5000

Mark Court / Mary-Jane Johnson / Stasa Filiplic

 

Notes for editors:

About Abcam plc

Abcam is a producer and distributor of research-grade antibodies headquartered in Cambridge, United Kingdom, with offices in Cambridge, Massachusetts, USATokyo, Japan and Hong Kong. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third-party produced antibodies to academic and commercial users throughout the world. Product ordering is available through the Company's website www.abcam.com, where customers are also able to access up-to-date and detailed technical product data sheets. All the antibodies are sold under the Abcam brand name and the Company's vision is to build the world's largest online resource of high-quality and commercially viable antibodies. Abcam now has an online catalogue of over 56,000 products, most of which are antibodies, from over 250 suppliers and employs 243 staff in its four operating companies.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSKZLBBKFBEFBE
Date   Source Headline
7th Jun 20067:00 amRNSTrading Update
9th May 20067:02 amRNSCommercial Development Appt.
27th Mar 200612:06 pmRNSDirector/PDMR Shareholding
14th Feb 20067:01 amRNSInterim Results
31st Jan 20067:01 amRNSNotification of Results
22nd Dec 20054:08 pmRNSDirectors Shareholding
3rd Nov 20057:00 amRNSFirst Day of Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.